IgG Inhibitors

Common IgG Inhibitors include, but are not limited to Prednisone CAS 53-03-2, Cyclophosphamide CAS 50-18-0, Mycophenolate mofetil CAS 128794-94-5, Azathioprine CAS 446-86-6 and Leflunomide CAS 75706-12-6.

Immunoglobulin G (IgG) is one of the primary classes of antibodies present in the circulatory system and various bodily fluids. These antibodies play a crucial role in the adaptive immune response, providing long-term protection against pathogens. Structurally, IgG molecules are Y-shaped, consisting of two identical heavy chains and two identical light chains. The tips of the "Y" contain regions known as antigen-binding sites, which can recognize and bind to specific structures (antigens) on the surfaces of pathogens, toxins, or other foreign substances. Once bound, IgG can recruit other immune cells or components to neutralize or eliminate the threat. In addition to this, IgG antibodies also play a role in various immune regulatory functions, including antibody-dependent cellular cytotoxicity (ADCC) and complement activation.

IgG inhibitors are molecules designed to target and modulate the function or abundance of IgG antibodies. These inhibitors can work through a variety of mechanisms. Some might prevent the production of IgG by affecting the cells responsible for their synthesis, namely the B cells. Others might bind directly to IgG molecules, preventing them from interacting with their target antigens or interfering with their downstream effector functions. Yet another group might block the receptors on immune cells that recognize the Fc region of IgG, thereby affecting the ability of IgG to elicit an immune response. The development and study of IgG inhibitors offer valuable tools for understanding the complex roles that these antibodies play in immunity, as well as the broader interactions and regulations within the immune system.